Drug Trial Radar · NCT04171739
Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim
Last checked: Nov 19, 2026Latest source record: Jul 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Nov 18, 2019
Primary completion
Feb 11, 2020
Study completion Feb 11, 2020
Sponsor
- Lead sponsor
- F2G LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Hammersmith Medicines Research
- First posted
- Nov 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, single-centre, fixed-sequence, open label, drug-drug interaction study in 2 groups of healthy subjects. Group A: to evaluate the effects of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), upon the pharmacokinetics of olorofim . Group B: t o evaluate the effects rifampicin, a strong inducer of CYP3A, upon the pharmacokinetics of olorofim .
Conditions
- Healthy
Interventions
Itraconazole oral solutionDrug
200 mg once daily on Days 6 to 15
Rifampicin Oral CapsuleDrug
600 mg once daily on Days 6 to 15
OlorofimDrug
Single oral dose on Days 1 and 11
Primary outcomes
What the sponsor says the trial is designed to measure.
- maximum plasma concentration (Cmax) for olorofim.Time frame: 16 days
- Area under the concentration-time curve to time of last quantifiable concentration (AUC0-tlast) for olorofim.Time frame: 16 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hammersmith Medicines Research
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.